MeCure (*8*) Plc has opened a suggestion of as much as N14 billion Series 8 Commercial Paper underneath its N40 billion Commercial Paper Programme.
The Lagos-based producer of medicines and multivitamins has been utilizing the market to lift cash for its short-term working capital wants.
This provide carries an implied annual yield of 21%. Investors holding the paper for its full 267-day period would earn roughly 15.36% on the quantity invested, earlier than relevant deductions, offered MeCure repays in full.
The provide opened on Wednesday, October 14, 2026, and closes on Tuesday, October 20, 2026.
What the provide round is saying
- Issuer: MeCure (*8*) Plc.
- Programme dimension: N40 billion.
- Series: 8 — goal dimension: Up to N14 billion.
- Tenor: 267 days.
- Discount charge: 18.2036% each year.
- Gross implied yield: 21% each year, said as inclusive of withholding tax.
- Allotment date: Tuesday, October 20, 2026.
- Settlement date: Wednesday, October 21, 2026.
- Maturity date: Thursday, July 15, 2027.
- Minimum subscription: N5 million and multiples of N1,000 thereafter.
- Issuer scores said in the provide: A1 from DataPro and A3 from GCR.
- Listing: Nigerian Exchange Limited and/or FMDQ Securities Exchange Limited.
The provide:
The issuance follows MeCure’s provide of as much as N10 billion Series 7 commercial paper in February 2026, which carried a 269-day tenor and a gross annualised yield of 21.75%.
- The newest provide will increase the fundraising goal by N4 billion, whereas providing a yield 0.75 share factors decrease over an identical interval.
- Proceeds will assist working capital, offering funding for the corporate’s operations whereas it converts manufacturing and gross sales into buyer receipts.
- Investors buy the paper under its compensation worth and obtain that worth at maturity.
On N5 million truly invested, the said annualised yield would generate about N768,000 in gross earnings over 267 days, utilizing a 365-day calculation foundation.
Total proceeds can be roughly N5.768 million, earlier than relevant deductions and topic to full compensation.
Investment case
MeCure’s 21% annual yield is increased than the 17.16% and 18.91% provided by six-month and one-year Treasury payments on the October 14 public sale.
- Investors earn extra for lending to the corporate, though MeCure’s paper runs for a unique interval of 267 days.
- The yield additionally stands above September’s 14.63% inflation charge, suggesting a chance to develop cash sooner than costs. The precise profit will depend upon taxes, charges and the way inflation adjustments earlier than compensation.
- The extra essential query is whether or not MeCure can repay.
MeCure’s announcement that it totally repaid its N3 billion bond in April 2026 provides some reassurance about its means to honour debt obligations.
Its rising enterprise gives additional assist. Revenue elevated 20.4% to N44.85 billion in H1 2026, whereas decrease advertising and marketing bills helped working revenue rise sooner, by 41% to N10.90 billion.
- MeCure’s enlargement is rising its funding wants. The firm invested N16.69 billion in services and tools throughout H1 2026, properly above the N1.45 billion in money generated from operations. Borrowing and current money helped fund the funding, leaving N2.07 billion in money at June.
- Total borrowings elevated 19.6% from December to N66.17 billion—about N3 borrowed for each N1 of shareholders’ funds.
- The rising debt burden provides to the significance of managing borrowing prices. Finance prices rose 54.9% to N5.93 billion, absorbing 54% of working revenue, in contrast with 49% a yr earlier.
MeCure’s working revenue nonetheless lined these prices, however they took a bigger share of its earnings regardless of the expansion in the enterprise.
The new services may assist reverse that development in the event that they generate sufficient extra gross sales and money to outpace the related prices. For CP buyers, compensation confidence will depend upon these money receipts and the funding accessible when the paper matures.
Investor takeaways
The provide gives a gross annualised yield of 21%, equal to roughly 15.36% over 267 days.
- Sales and working revenue are rising, supporting the corporate’s earnings base.
- Expansion may strengthen future manufacturing and gross sales, however requires funding earlier than the complete advantages materialise.
Investors ought to verify internet earnings after relevant deductions and plan across the July 2027 maturity.
Risk concerns
The principal concerns are rising financing prices, money dedicated to enlargement and the timing of buyer receipts.
- Further borrowing may take in a part of the profit from stronger working earnings.
- Slower collections or delays in producing returns from new capability may improve funding wants.
- Investors searching for to promote earlier than maturity might obtain a unique return from the marketed yield.
Sustained money era and a transparent compensation funding plan would supply extra reassurance alongside MeCure’s earnings progress and said credit score scores.
